From OncLive
Three recent drug approvals have shifted the landscape in the second-line setting for renal cell carcinoma (RCC), and researchers are now setting their sights on transforming upfront care, according to Chung-Han (Joe) Lee, MD
See more at: http://www.onclive.com/web-exclusives/after-secondline-rcc-approvals-focus-shifts-to-frontline#sthash.4zOJZVsu.dpuf